Different doses of Rituximab for the therapy of Neuromyelitis optica spectrum disorder: A systematic review and meta-analysis-Reference-Cited by-同舟云学术

Different doses of Rituximab for the therapy of Neuromyelitis optica spectrum disorder: A systematic review and meta-analysis

Published:2022-12 Issue: Volume:68 Page:104127
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Wei Kenhui^ORCID,Nie Qianqian,Zhu Yunfei,Lu Haifeng,Xue Qun,Chen Gang

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference34 articles.

1. Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study;Annovazzi;J. Neurol.,2016

2. Disease course, progression and activity of neuromyelitis optica (NMOSD) in patients who were treated with Rituximab, 6 and 12 months after receiving the first dose of drug, in Isfahan city;Ashtari;Mult. Sclerosis Rel. Disord.,2019

3. Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study;Cabre;J. Neurol.,2018

4. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies;Carnero Contentti;J. Neuroinflamm.,2021

5. Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders;Correa-Díaz;Mult. Sclerosis Rel. Disord.,2021

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term efficacy and safety of rituximab in the treatment of neuromyelitis Optica Spectrum disorder;Multiple Sclerosis Journal - Experimental, Translational and Clinical;2024-04

2. Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder;Scientific Reports;2024-02-12

3. Efficacy and safety of low- and ultralow-dose rituximab in neuromyelitis optica spectrum disorder;Journal of Neuroimmunology;2024-02

4. Monoclonal antibody therapies for aquaporin-4-immunoglobulin G-positive neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease;Saudi Journal of Ophthalmology;2023-10-24

5. Eculizumab for a catastrophic relapse in NMOSD: case report;Neurological Sciences;2023-07-27